GENE (Genetic Technologies Ltd) Operating Margin

The synergy between bioinformaticians and geneticists provides Genetic Technologies (GENE) with high development precision. The operating profit margin clearly demonstrates this efficiency, where -140.30 determines the latest valuation metric. Strict FDA certifications and patents for oncology tests form the business foundation, although insurance payouts and limited liquidity reserves constrain growth.
Financial and market metric breakdowns for Genetic Technologies Ltd (GENE)

Operating margin is calculated as the ratio of operating profit to revenue, reflecting cost management efficiency and the business's ability to generate income before financial expenses and taxes. For Genetic Technologies (GENE), this metric confirms the monetization of patent protection and insurance payments, as the high cost of switching to alternative diagnostic systems ensures the stability of the operating margin.